Why is NMOSD patient recruitment so difficult?

NMOSD enrollment is hard because the diagnosis is hard. NMOSD is frequently mistaken for multiple sclerosis, confirmation depends on serologic testing and specialist evaluation, and eligibility turns on serostatus (AQP4, MOG, or seronegative) and recent relapse activity. The population is small and dispersed, and patients are seen by neurologists and neuro-ophthalmologists rather than found through general outreach. Generic, ad-volume recruitment surfaces look-alike patients who fail screening and rarely reaches the right specialists at all.

How does Leapcure find and qualify NMOSD patients?

We lead with physician and specialist outreach, the neurologists and neuro-ophthalmologists who actually diagnose NMOSD and catch the cases mistaken for MS, and add precision digital for volume. Our Patient Success Team then confirms serostatus and eligibility through real human conversations and an in-house clinical-eligibility review, covering AQP4, MOG, and seronegative status and recent relapse activity. Patients arrive at your sites eligible, prepared, and documentation-ready, so sites get ready candidates, not work.

How quickly can Leapcure begin NMOSD patient recruitment?

Leapcure can mobilize existing rare-disease networks within 2 days of program launch. Because we already hold specialist and patient relationships in the rare, immune-mediated neuro-immunology community, we do not start from a cold list, which is what lets us reach a small, dispersed NMOSD population quickly.

Can Leapcure work alongside our sites and other recruitment vendors?

Yes. Our channels are designed to complement site and vendor efforts rather than compete with them. We lead with specialist outreach and precision digital, confirm serostatus and eligibility before referral, and hand sites prepared candidates, so we add reach and readiness without adding coordinator burden.

How does Leapcure reduce burden on NMOSD trial sites?

Every patient is engaged through real human conversations, not automated screening, plus an in-house clinical-eligibility review, so serostatus and eligibility are confirmed and patients are documentation-ready before any site referral. Our Patient Success Team carries the eligibility detail and supports patients and families through a relapsing disease, which reduces coordinator burden, screen fails, and dropout on scarce specialist sites.

NMOSD enrollment is hard because the diagnosis is hard. We reach patients through specialist networks and confirm serostatus before site referral.

Name: Neuromyelitis Optica Spectrum Disorder Clinical Trial Recruitment | Leapcure
Creator: Leapcure

Leapcure reaches NMOSD patients through neurologists and neuro-ophthalmologists, confirms serostatus before your sites do, and brings a documented enrollment track record across rare, immune-mediated disease.

Talk to our NMOSD team See how it works →

80%

Enrollment contribution

in an adjacent rare autoimmune neuromuscular study (Myasthenia Gravis, Phase 2)

Physicians referring patients to site

across one country in a rare-disease program

43%

Leapcure's share of total enrollments

in an adjacent Phase 3 autoimmune study (Dermatomyositis)

2 days

To mobilize

existing rare-disease networks

Understanding NMOSD as a Clinical Trial Indication

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, immune-mediated disease of the central nervous system in which the immune system attacks the optic nerves and spinal cord, threatening vision and mobility with each relapse. Most cases are defined by serostatus: aquaporin-4 antibodies (AQP4-IgG), MOG antibodies, or seronegative disease, and that distinction shapes both diagnosis and trial eligibility. NMOSD belongs to the family of rare, immune-mediated neuro-immunology conditions alongside Myasthenia Gravis and CIDP, and it carries the same recruitment profile: a small, dispersed population reached only through the specialists and communities they already trust.

NMOSD is genuinely hard to enroll because it is genuinely hard to diagnose, and it is frequently mistaken for multiple sclerosis, which delays the correct diagnosis and the right treatment. Confirmation depends on serologic testing and specialist evaluation, eligibility turns on serostatus (AQP4, MOG, or seronegative) and recent relapse activity, and patients are seen by neurologists and neuro-ophthalmologists rather than surfaced through general outreach. Generic, ad-volume recruitment surfaces MS and other look-alike patients who fail screening, and rarely reaches the right specialists at all.

Leapcure recruits for exactly this kind of trial. We reach patients through the neurologists and neuro-ophthalmologists who actually diagnose NMOSD, bring volume through precision digital, and lean on a Patient Success Team that confirms serostatus and eligibility before site referral and supports patients and their families through a relapsing, high-burden disease. We have direct NMOSD experience, and to date it is qualitative, so we state our NMOSD model plainly and show our numbers as what they are: a documented track record across rare, immune-mediated disease, labeled by indication. In an adjacent Phase 2 rare neuromuscular study (Myasthenia Gravis) Leapcure contributed about 80% of enrollment, and in an adjacent Phase 3 autoimmune study (Dermatomyositis) Leapcure drove about 43% of total enrollments. We never state or imply an NMOSD-specific result we do not yet hold.

The Challenge

NMOSD trial recruitment demands more than reach. It demands specialist access, serostatus confirmation before referral, and the patient trust that only neurologists, neuro-ophthalmologists, and trusted communities carry.

The diagnosis is hard, so the enrollment is hard

NMOSD is frequently mistaken for multiple sclerosis, and confirmation depends on serologic testing and specialist evaluation. Eligibility turns on serostatus (AQP4, MOG, or seronegative) and recent relapse activity. Generic campaigns surface MS and other look-alike patients who fail screening and spend scarce specialist-site time on people the protocol cannot use.

Our Patient Success Team confirms serostatus and eligibility detail before any site referral, so patients arrive ready rather than as work for your coordinators.

Patients are reached through specialists, not list buys

People with NMOSD are diagnosed and managed by neurologists and neuro-ophthalmologists, and the patient community is small and tight-knit. Cold digital and purchased lists do not reach them. Recruitment works when research reaches patients through the specialists they already rely on.

In a rare-disease program, Leapcure had 50 physicians referring patients to site across one country, the specialist channel NMOSD depends on, and can mobilize existing rare-disease networks within 2 days of program launch.

It is a rare, dispersed, serostatus-driven disease

NMOSD is rare and dispersed, so the eligible pool in any one region is tiny, and serostatus splits it further across AQP4, MOG, and seronegative disease. It sits in the same rare, immune-mediated neuro-immunology family as Myasthenia Gravis and CIDP, the family Leapcure recruits for, where reaching enough eligible patients means reaching them across many regions at once.

Leapcure recruits across this family, with adjacent Phase 2 and Phase 3 autoimmune programs that prove the specialist-outreach and patient-support model NMOSD needs.

Relapsing, high-burden disease raises the stakes

NMOSD relapses threaten vision and mobility, and trials run long, so keeping enrolled patients engaged and supported matters as much as finding them. A recruiter who hands sites referral volume rather than prepared, supported patients leaves sites carrying the burden and the study exposed to dropout.

A dedicated Patient Success Team supports patients and families from first contact through enrollment and relapse, reducing site burden and screen fails.

How Leapcure recruits for NMOSD and rare neuro-immunology trials

We lead with physician and specialist outreach for serostatus-sensitive reach and to catch the MS misdiagnosis, use precision digital for volume, and run serostatus and eligibility confirmation plus family support through a Patient Success Team.

Reach patients through the specialists who diagnose them

We lead with physician and specialist outreach, the neurologists and neuro-ophthalmologists who actually see NMOSD and catch the cases misdiagnosed as MS, and pair it with precision digital for volume. This is the serostatus-sensitive reach that cold digital cannot match.

Confirm serostatus and eligibility before site referral

Our Patient Success Team works the eligibility detail NMOSD trials turn on, serostatus (AQP4, MOG, or seronegative) and recent relapse activity, through real human conversations and an in-house clinical-eligibility review. Sites conduct official screening and receive patients who are eligible, prepared, and documentation-ready.

Support patients and families through a relapsing disease

A dedicated Patient Success Team supports each patient and their family from first contact through enrollment, carrying the eligibility detail that otherwise lands on sites. In a relapsing, vision and mobility threatening disease, this continuity is what reduces dropout and keeps long studies moving.

Adjacent proof, shown as adjacent: a documented enrollment track record across rare, immune-mediated disease

Challenge Context

Programs

Adjacent rare, immune-mediated programs in the same family as NMOSD: Myasthenia Gravis (Phase 2) and Dermatomyositis (Phase 3).

Challenge

Rare, serostatus- and eligibility-sensitive populations reached through specialist networks, the same recruitment profile NMOSD carries.

Why it is relevant to NMOSD

It proves the specialist outreach, pre-screening, and patient-support model NMOSD needs. This is adjacent proof, never an NMOSD-specific result.

Results & Metrics

Enrollment contribution (adjacent, Myasthenia Gravis, Phase 2)

Leapcure contributed about 80% of enrollment in an adjacent Phase 2 rare neuromuscular study.

Phase 3 deep-dive (adjacent, Dermatomyositis)

Leapcure drove about 43% of total study enrollments (13 enrollments) through grassroots partnerships, digital, physician outreach, and a Patient Success Team experienced with the patient journey.

Physician-network reach (adjacent rare-disease program)

Leapcure had 50 physicians referring patients to site across one country, with referrals and insights driving long-term outreach, the specialist channel NMOSD depends on.

Wider rare immune-mediated portfolio

Additional adjacent contribution includes Thyroid Eye Disease (about 78%, Phase 2) and Idiopathic Pulmonary Fibrosis (about 75%, Phase 3).

NMOSD experience (shown qualitatively)

Our direct NMOSD experience is qualitative to date: we reached serostatus-sensitive, frequently misdiagnosed patients through specialist outreach, used digital for volume, and our Patient Success Team carried eligibility detail and family support. This is the model NMOSD needs.

Four channels. Built for NMOSD. Specialist reach first

NMOSD is won on specialist reach, serostatus confirmation, and trust, not ad volume. Leapcure leads with physician and specialist outreach, adds precision digital for volume, runs serostatus and eligibility pre-screening through a Patient Success Team, and brings answer-engine visibility.

Channel 1: Physician and specialist outreach

•We lead with the neurologists and neuro-ophthalmologists who actually diagnose NMOSD and catch the cases mistaken for MS, for serostatus-sensitive reach that cold digital cannot match.
•In a rare-disease program, this is the channel through which Leapcure had 50 physicians referring patients to site across one country, with referrals and insights driving long-term outreach.
•Specialist relationships, not purchased lists, are what reach a small, dispersed NMOSD population.

Channel 2: Precision digital for volume

•Precision digital campaigns are mapped to your eligibility criteria and geographies to bring volume on top of specialist reach.
•Digital brings volume; specialist outreach brings the serostatus-sensitive reach that finds qualified NMOSD patients.
•Spend is rebalanced in real time based on site capacity and screening performance.

Channel 3: Patient Success and serostatus pre-screening

•Real human conversations plus an in-house clinical-eligibility review handle the detail NMOSD trials turn on: serostatus (AQP4, MOG, or seronegative) and recent relapse activity.
•Patients are confirmed and documentation-ready before any site referral, so sites get ready candidates, not work.
•A dedicated Patient Success Team supports patients and families through a relapsing, high-burden disease, reducing dropout and site burden.

Channel 4: AEO and AI-search visibility, defined honestly

•Patients and sponsors increasingly ask ChatGPT, Perplexity, and Google's AI Overview about trials and recruitment. We make your trial's information genuinely retrievable for those engines.
•The advantage is structure (crawlable, server-rendered prose and clear Q&A), authority (first-party data, dated stats, cited sources, a visible last-updated date), and presence in the specialist, registry, and community sources AI engines actually cite.
•This is not schema tricks, markup, or content written for machines. We never promise AI visibility through markup.

Living with NMOSD? A clinical trial may be an option to explore.

If you are living with NMOSD, or caring for someone who is, a clinical trial may offer access to investigational treatments alongside your existing care, never instead of it. We know NMOSD is a rare, relapsing condition that is often mistaken for other diseases before it is correctly diagnosed, and we will never pressure you. Leapcure's team answers your questions honestly, explains what a trial involves, and supports you and your family step by step.

See if a trial may be right for you

Leapcure is built for exactly this kind of trial: rare, immune-mediated, serostatus-driven, frequently misdiagnosed, and dependent on specialist reach and patient trust. We reach NMOSD patients through the neurologists and neuro-ophthalmologists who diagnose them, confirm serostatus before your sites do, and support patients and families through relapse. We bring a documented enrollment track record across rare, immune-mediated disease, with about 80% contribution in an adjacent Phase 2 program and about 43% of total enrollments in an adjacent Phase 3 study, and we can mobilize existing rare-disease networks within 2 days of program launch. That is the partner you want on an NMOSD trial.

Talk to our NMOSD team